Emergent announces positive results from phase 1b study of otlertuzumab in ... pharmabiz.com Emergent BioSolutions Inc., a specialty pharmaceutical company, has reported preliminary results from a phase Ib single-arm, open-label study evaluating the safety and efficacy of otlertuzumab (TRU-016) in combination with rituximab in people with ... |